title: Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene.
abstract: Infection by herpesviruses causes a dramatic disturbance of PML oncogenic domains (PODs) that has been suggested to be essential for viral lytic replication. Several proteins from Kaposi's sarcoma-associated herpesvirus (KSHV) have been tested as putative POD-disrupting factors with negative results. Here, we show that LANA2, a viral protein that is absolutely required for the viability and proliferation of KSHV-infected primary effusion lymphoma (PEL) cells, increases the levels of SUMO2-ubiquitin-modified PML and induces the disruption of PODs by a proteasome-mediated mechanism. In addition, we demonstrate that this disruption is largely dependent on both the integrity of a SUMO interaction motif in LANA2 and the lysine 160 from PML. Moreover, silencing of LANA2 expression in PEL cells by RNA interference led to an increase in the PML levels. Finally, we demonstrate that LANA2 relieves PML-mediated transcriptional repression of survivin, a protein that directly contributes to malignant progression of PEL. This represents the first example of inactivation of these important antiviral structures by KSHV.
authors: Departamento Microbiología II, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal, 28040 Madrid, Spain.
authors: Laura
authors: L
authors: Marcos-Villar
authors: Fernando
authors: F
authors: Lopitz-Otsoa
authors: Pedro
authors: P
authors: Gallego
authors: Cesar
authors: C
authors: Muñoz-Fontela
authors: José
authors: J
authors: González-Santamaría
authors: Michela
authors: M
authors: Campagna
authors: Gao
authors: G
authors: Shou-Jiang
authors: Manuel S
authors: MS
authors: Rodriguez
authors: Carmen
authors: C
authors: Rivas
mesh_terms: D000956:Antigens, Viral / Q000378:metabolism*; D045744:Cell Line, Tumor; D055785:Gene Knockdown Techniques / Q000379:methods; D020868:Gene Silencing; D019288:Herpesvirus 8, Human / Q000502:physiology*; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis*; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000071156:Promyelocytic Leukemia Protein; D000077022:Survivin; D014157:Transcription Factors / Q000037:antagonists & inhibitors*; D025521:Tumor Suppressor Proteins / Q000037:antagonists & inhibitors*
chemical_list: D000956:Antigens, Viral; C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D000077022:Survivin; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C109540:latency-associated nuclear antigen; C070576:PML protein, human